secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2023-04-19T23:59:59+00:00
Accession:  0001628280-23-012020
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q1 revenue $9.7B, adj EPS $1.03; base business organic growth 10.0%
--------------------------------------------------------------------------

- Q1 GAAP EPS $0.75; adjusted EPS $1.03; revenue $9.747B, down 18.1% reported, but organic base business up 10.0%.
- Full-year 2023 adjusted EPS guidance unchanged at $4.30-$4.50; COVID testing-related sales forecast ~$1.5B.
- Medical Devices organic sales grew 12.4%; FreeStyle Libre sales $1.2B with ~50% U.S. growth.
- Nutrition organic sales up 10.3% (Pediatric +18.4% organic); Diagnostics ex-COVID tests organic +4.4%.
- Dividend of $0.51/share declared, payable May 15; 51 consecutive years of dividend increases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000162828023012020/0001628280-23-012020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000162828023012020/abt-20230419.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-012020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer